Trial Profile
A Phase I/II Study of JR-141 (Idursulfase) in Patients With Mucopolysaccharidosis Type II
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Pabinafusp alfa (Primary)
- Indications Mucopolysaccharidosis II
- Focus Adverse reactions; First in man; Registrational
- Sponsors JCR Pharmaceuticals
- 27 Feb 2023 Long-term safety and efficacy and behavioral effects of JR-141 were presented at the 19th Annual WORLDSymposium™ 2023 in Orland, FL, USA.
- 27 Feb 2023 Results presented in a JCR Pharmaceuticals Media Release.
- 23 Mar 2021 According to a JCR Pharmaceuticals media release, the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved IZCARGO (pabinafusp alfa 10 mL, intravenous drip infusion) for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). The approval is based on of evidence from non-clinical and clinical studies(including this and a phase II/III study).